Needham & Company LLC restated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $4.25 price target on the stock.
Separately, StockNews.com began coverage on shares of OncoCyte in a research note on Tuesday. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.06.
Get Our Latest Stock Report on OCX
OncoCyte Trading Up 0.3 %
OncoCyte (NASDAQ:OCX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.
Insider Activity at OncoCyte
In related news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Andrea S. James acquired 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average cost of $2.97 per share, with a total value of $99,999.90. Following the acquisition, the chief financial officer now directly owns 33,670 shares in the company, valued at $99,999.90. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the acquisition, the insider now directly owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 1.58% of the stock is owned by company insiders.
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Featured Stories
- Five stocks we like better than OncoCyte
- Learn Technical Analysis Skills to Master the Stock Market
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is a Special Dividend?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.